Seer, Inc.
2.2200-0.07 (-3.06%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · SEER · USD
Key Stats
Market Cap
125.07MP/E (TTM)
-Basic EPS (TTM)
-1.39Dividend Yield
0%Recent Filings
8-K
Seer appoints finance expert Ro
Seer, Inc. appointed Isaac Ro to its board on September 2, 2025, adding him to the Audit Committee as the financial expert to meet Nasdaq rules. Ro, a Catalio Capital partner with CFO stints at Sema4 and Thrive Earlier Detection, brings life sciences finance savvy. He received options for 61,000 shares and RSUs for 41,000 shares, vesting over three years. This bolsters governance amid growth pushes.
10-Q
Q2 FY2025 results
Seer, Inc. filed its 10-Q for the quarter ended June 30, 2025, but the document provided contains only the cover page and table of contents, with no financial statements, MD&A, or notes included. Without access to revenue, profitability, cash flow, or balance sheet details, key metrics like y/y or q/q changes in revenue, EPS, or free cash flow cannot be analyzed or reported. Non-GAAP metrics are not disclosed in the 10-Q. Liquidity and debt positions remain unreported. No M&A, impairments, or regulatory events are detailed. Competition in the biotech space poses ongoing risks to market position.
8-K
Seer Q2 revenue surges 32%
Seer, Inc. reported Q2 2025 revenue of $4.1 million, up 32% from $3.1 million last year, fueled by stronger product and service sales amid macroeconomic headwinds. The company launched its high-throughput Proteograph ONE assay and SP200 automation instrument, boosting platform scalability, and inked a collaboration with Korea University for a 20,000-sample proteomics study on young adult cancers. Operating expenses dropped 21% to $22.6 million, narrowing net loss to $19.4 million; cash reserves stood at $263.3 million. Seer reiterated full-year revenue guidance of $17-18 million. Innovation drives growth, yet funding burn persists.
8-K
Nasdaq audit compliance issue
Seer, Inc. disclosed on July 7, 2025, that its Audit Committee will fall short of Nasdaq's three-member requirement and financial expertise standard following the annual stockholder meeting, prompting notification of noncompliance while seeking the cure period to adjust board composition. Stockholders elected six directors—Omid Farokhzad, M.D., Meeta Gulyani, Terrance McGuire, Robert Langer, Sc.D., Dipchand (Deep) Nishar, and Nicolas Roelofs, Ph.D.—with strong support, and ratified Deloitte & Touche LLP as auditors for 2025. Compliance hinges on timely fixes. Risks could delay resolution.
8-K
Seer Q1 revenue surges 37%
Seer, Inc. reported first-quarter 2025 revenue of $4.2 million, up 37% from $3.1 million a year earlier, fueled by stronger product and service sales amid industry headwinds. Gross margin hit 49%, while operating expenses dropped 14% to $22.8 million, trimming net loss to $19.9 million. Cash reserves stood at $285 million. The company shipped as many instruments in Q1 as all of 2024. It reaffirmed full-year revenue guidance of $17-18 million.
ADPT
Adaptive Biotechnologies Corpor
16.80-0.10
CAI
Caris Life Sciences, Inc.
29.43-0.95
ILMN
Illumina, Inc.
95.03-2.77
LAB
Standard BioTools Inc.
1.19-0.08
MRVI
Maravai LifeSciences Holdings,
3.07-0.16
NAUT
Nautilus Biotechnology, Inc.
1.41-0.02
PACB
Pacific Biosciences of Californ
2.01+0.04
SEOVF
SERNOVA BIOTHERAPEUTICS INC.
0.12+0.00
TECH
Bio-Techne Corp
62.02-1.92
ZIVO
Zivo Bioscience, Inc.
16.99-0.01